• Skip to main content
  • Skip to footer

PeDRA

Pediatric Dermatology Research Alliance

  • Pay 2021 Membership Dues
  • Our Membership
  • Login
MENUMENU
  • Contact
  • For Patients & Families
        • Patient Support
        • Patient Education
        • SPD's Find a Pediatric Dermatologist
        • Clinical Trials
        • Patient Advisory Committee
        • Learn more about PeDRA’s efforts to build capacity for patient engagement in pediatric dermatology research.

           

  • Education and Events
        • Virtual Education
        • PeDRA Podcasts
        • Mentorship Program
        • Early Career Support
        • 2021 PeDRA Annual Conference
        • Past PeDRA Conferences
        • Upcoming Events
        • Education and Events Archive
        • Save the Date!

          The 2021 PeDRA Annual Conference will take place October 14-16, 2021 in Bethesda, MD.

  • Research
        • Grants & Awards
        • Studies
        • Focused Study Groups
        • Publications
        • Clinical Trials
        •  

          Thanks to everyone who applied for a 2020 PeDRA Research Grant, Weston CDA, or Consensus Grant!

          2021 Research Fellowships will be our next open funding opportunity, with a deadline to apply of April 1, 2021.

  • About
        • Mission & Vision
        • Leadership & Staff
        • Annual Reports
        • News Archive
        • Our Supporters
        • Our Membership
        • Our Committees
        • Getting to Know You
        • PeDRA is an independent 501(c)(3) nonprofit organization driven by the mission to create, inspire, and sustain research to prevent, treat, and cure childhood skin disease.

  • Member Login

Characterization of Lipoprotein Composition and Function in Pediatric Psoriasis Before and After Treatment

July 15, 2020 By Katherine Devenport

Principal Investigator:

Amy Paller, MD
Northwestern University

Overview:

Psoriasis is a chronic inflammatory skin disease associated with early onset cardiovascular disease. Despite studies demonstrating high cholesterol, increased diabetes and
higher rate of obesity in psoriasis, these traditional risk factors only explain a fraction of total cardiovascular risk in psoriasis. One-third of the psoriasis patients start developing psoriatic plaques during childhood and studies have shown that the children with psoriasis have similar or higher risk for obesity and future problems with high cholesterol and diabetes. In fact, children have been shown to have abnormal cholesterol as early as age 13 years in psoriasis. However, little is known about how pediatric psoriasis severity affects cholesterol function, including its relationship with proteins involved in inflammation. Importantly, whether treatment of pediatric psoriasis early in the life leads to improvement in cholesterol function and overall lipoprotein
composition is unknown. Therefore, the goal of this proposal is to understand the effect of disease activity and psoriasis treatment on cholesterol and metabolic markers in pediatric
psoriasis.

Status:

This project was funded as a 2018 PeDRA and NPF Pediatric Psoriasis Challenge Grant and is currently underway.

Filed Under: Active Studies, Inflammatory Skin Disease, Uncategorized

Footer

  • Our Membership
  • For Patients
  • For Researchers
  • Forum
  • Facebook
  • Instagram
  • LinkedIn
  • Twitter
Sign up to receive emails from PeDRA
Join PeDRA
Donate

Copyright © 2021 · Pediatric Dermatology Research Alliance (PeDRA) · All Rights Reserved. · Privacy Policy